QQQ   444.84 (+0.00%)
AAPL   172.17 (-0.66%)
MSFT   421.32 (-0.03%)
META   489.15 (-0.95%)
GOOGL   151.22 (+0.23%)
AMZN   180.60 (+0.43%)
TSLA   175.83 (-2.22%)
NVDA   904.89 (+0.26%)
NIO   4.50 (-3.64%)
AMD   180.36 (+0.43%)
BABA   72.45 (+1.20%)
T   17.67 (+0.68%)
F   13.27 (+1.61%)
MU   117.92 (-1.02%)
CGC   8.88 (-7.02%)
GE   175.91 (-2.34%)
DIS   122.40 (+1.17%)
AMC   3.68 (-15.21%)
PFE   27.88 (+0.36%)
PYPL   67.26 (+1.04%)
XOM   116.23 (+1.10%)
QQQ   444.84 (+0.00%)
AAPL   172.17 (-0.66%)
MSFT   421.32 (-0.03%)
META   489.15 (-0.95%)
GOOGL   151.22 (+0.23%)
AMZN   180.60 (+0.43%)
TSLA   175.83 (-2.22%)
NVDA   904.89 (+0.26%)
NIO   4.50 (-3.64%)
AMD   180.36 (+0.43%)
BABA   72.45 (+1.20%)
T   17.67 (+0.68%)
F   13.27 (+1.61%)
MU   117.92 (-1.02%)
CGC   8.88 (-7.02%)
GE   175.91 (-2.34%)
DIS   122.40 (+1.17%)
AMC   3.68 (-15.21%)
PFE   27.88 (+0.36%)
PYPL   67.26 (+1.04%)
XOM   116.23 (+1.10%)
QQQ   444.84 (+0.00%)
AAPL   172.17 (-0.66%)
MSFT   421.32 (-0.03%)
META   489.15 (-0.95%)
GOOGL   151.22 (+0.23%)
AMZN   180.60 (+0.43%)
TSLA   175.83 (-2.22%)
NVDA   904.89 (+0.26%)
NIO   4.50 (-3.64%)
AMD   180.36 (+0.43%)
BABA   72.45 (+1.20%)
T   17.67 (+0.68%)
F   13.27 (+1.61%)
MU   117.92 (-1.02%)
CGC   8.88 (-7.02%)
GE   175.91 (-2.34%)
DIS   122.40 (+1.17%)
AMC   3.68 (-15.21%)
PFE   27.88 (+0.36%)
PYPL   67.26 (+1.04%)
XOM   116.23 (+1.10%)
QQQ   444.84 (+0.00%)
AAPL   172.17 (-0.66%)
MSFT   421.32 (-0.03%)
META   489.15 (-0.95%)
GOOGL   151.22 (+0.23%)
AMZN   180.60 (+0.43%)
TSLA   175.83 (-2.22%)
NVDA   904.89 (+0.26%)
NIO   4.50 (-3.64%)
AMD   180.36 (+0.43%)
BABA   72.45 (+1.20%)
T   17.67 (+0.68%)
F   13.27 (+1.61%)
MU   117.92 (-1.02%)
CGC   8.88 (-7.02%)
GE   175.91 (-2.34%)
DIS   122.40 (+1.17%)
AMC   3.68 (-15.21%)
PFE   27.88 (+0.36%)
PYPL   67.26 (+1.04%)
XOM   116.23 (+1.10%)
NASDAQ:HZNP

Horizon Therapeutics Public (HZNP) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$116.30
$116.30
50-Day Range
$112.60
$116.30
52-Week Range
$60.03
$116.38
Volume
N/A
Average Volume
2.50 million shs
Market Capitalization
$26.63 billion
P/E Ratio
62.19
Dividend Yield
N/A
Price Target
N/A
HZNP stock logo

About Horizon Therapeutics Public Stock (NASDAQ:HZNP)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

HZNP Stock News Headlines

5 Biotech Acquisition Targets To Accumulate In 2024
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Rule 17(e) Announcement - Horizon Therapeutics plc
Rule 17(d) Announcement - Horizon Therapeutics plc
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Rule 17(d) Announcement – Horizon Therapeutics plc
Improved Outlook For Horizon Therapeutics And Amgen
Horizon Therapeutics (HZNP) Receives a Hold from H.C. Wainwright
See More Headlines
Receive HZNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/08/2023
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:HZNP
CUSIP
44047T10
Employees
2,115
Year Founded
2008

Profitability

Net Income
$521.48 million
Pretax Margin
12.18%

Debt

Sales & Book Value

Annual Sales
$3.63 billion
Cash Flow
$7.05 per share
Book Value
$22.38 per share

Miscellaneous

Free Float
223,957,000
Market Cap
$26.63 billion
Optionable
Optionable
Beta
1.03

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Should I Buy Horizon Therapeutics Public Stock? HZNP Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Horizon Therapeutics Public was last updated on Monday, March 25, 2024 at 11:52 PM.

Pros

Here are some ways that investors could benefit from investing in Horizon Therapeutics Public Limited:

  • Horizon Therapeutics has shown consistent revenue growth over the past few quarters, indicating a strong financial performance.
  • The company has a diverse portfolio of innovative drugs, including treatments for rare diseases, which can provide a competitive edge in the pharmaceutical market.
  • Recent positive clinical trial results for their flagship product have boosted investor confidence in the company's future prospects.
  • Horizon Therapeutics' stock price has been steadily increasing, reflecting positive market sentiment and potential for further growth.
  • The company has a robust pipeline of new drugs in development, which could drive future revenue growth and expansion.

Cons

Investors should be bearish about investing in Horizon Therapeutics Public Limited for these reasons:

  • There is a level of regulatory uncertainty in the pharmaceutical industry that could impact the company's ability to bring new drugs to market.
  • Competition in the pharmaceutical sector is intense, which may pose challenges for Horizon Therapeutics to maintain market share and pricing power.
  • Market volatility and macroeconomic factors can influence the stock price of pharmaceutical companies, including Horizon Therapeutics.
  • Unexpected adverse events in clinical trials or regulatory setbacks could negatively impact the company's stock performance and reputation.
  • Investing in biopharmaceutical companies like Horizon Therapeutics carries inherent risks due to the complex nature of drug development and regulatory approvals.

HZNP Stock Analysis - Frequently Asked Questions

Should I buy or sell Horizon Therapeutics Public stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HZNP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HZNP, but not buy additional shares or sell existing shares.
View HZNP analyst ratings
or view top-rated stocks.

How were Horizon Therapeutics Public's earnings last quarter?

Horizon Therapeutics Public Limited (NASDAQ:HZNP) announced its quarterly earnings results on Tuesday, August, 8th. The biopharmaceutical company reported $1.20 earnings per share for the quarter, topping analysts' consensus estimates of $1.12 by $0.08. The biopharmaceutical company earned $945 million during the quarter, compared to analyst estimates of $873.52 million. Horizon Therapeutics Public had a net margin of 12.02% and a trailing twelve-month return on equity of 20.46%. Horizon Therapeutics Public's revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter last year, the company earned $1.07 EPS.

What is Timothy Walbert's approval rating as Horizon Therapeutics Public's CEO?

70 employees have rated Horizon Therapeutics Public Chief Executive Officer Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Horizon Therapeutics Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL).

Who are Horizon Therapeutics Public's major shareholders?

Horizon Therapeutics Public's stock is owned by many different retail and institutional investors. Top institutional investors include Highbridge Capital Management LLC (0.00%), Concourse Financial Group Securities Inc. (0.00%), Picton Mahoney Asset Management (0.00%), BCK Capital Management LP (0.00%), Simplex Trading LLC (0.00%) and Equitec Proprietary Markets LLC (0.00%). Insiders that own company stock include Aaron Cox, Andy Pasternak, Barry Moze, Brian K Beeler, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Paul W Hoelscher, Paul W Hoelscher, Sean M Clayton, Timothy P Walbert and William F Daniel.
View institutional ownership trends
.

Does Horizon Therapeutics Public have any subsidiaries?
The following companies are subsidiares of Horizon Therapeutics Public: Curzion Pharmaceuticals Inc., HZNP Canada Limited, HZNP Finance Limited, HZNP Limited, Horizon Medicines LLC, Horizon Ophthalmology Inc, Horizon Orphan Holdings LLC, Horizon Orphan LLC, Horizon Pharma Israel Holding Corp. Ltd, Horizon Therapeutics Capital Limited, Horizon Therapeutics Finance Limited, Horizon Therapeutics Finance S.à.r.l, Horizon Therapeutics GmbH, Horizon Therapeutics Holdings Limited, Horizon Therapeutics Investment Limited, Horizon Therapeutics Ireland DAC, Horizon Therapeutics LLC, Horizon Therapeutics Services LLC, Horizon Therapeutics Switzerland GmbH, Horizon Therapeutics Treasury DAC, Horizon Therapeutics USA Inc., Hyperion Therapeutics, Hyperion Therapeutics Ireland Holding Limited, Hyperion Therapeutics Ireland Operating Limited, Raptor Pharmaceuticals, River Vision Development Corp., Vidara Therapeutics, and Viela Bio Inc..
Read More
This page (NASDAQ:HZNP) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners